000			01773nam a22001577a 4500
999			_c519676 _d519676
008			220411b ||||| |||| 00| 0 eng d
100			_aBhadala, Tilkesh _932685
245			_aOximeter: Gasping for regulatory oxygen profiteering in oximeter and need for immediate regulation
260			_aIIPA Digest
300			_a3(2), Apr-Jun, 2021: p.26-30
520			_aThis article presents an analysis of ‘systemic loops’ in regulatory mechanisms during public health emergency, i.e. COVID-19 second wave. This ‘once in a century crisis’ has highlighted regulatory lapses and oversight in the functioning of the National Pharmaceutical Pricing Authority (NPPA). Taking specific case for oximeter, this article analyses that how the manufacturers and retailers used regulatory lapses for profiteering, rendering orders useless, toothless and ineffective, issued by National Pharmaceutical Pricing Authority (NPPA). Moreover, this underlines the problems in MRP regime and over reliance of regulator to depend on MRP as a key tool to regulate the prices. The later section of the article deals with the Drug Price Control Order, 2013 and powers provided by it to the NPPA- to take necessary measures to carry out its functions; ensuring quality, availability and affordability of the drugs. It also provides for viable alternatives to determine the prices using integration of data. The last part of article talks about possible impact of these regulatory lapses on income levels of lower-middle income groups and vulnerable sections of the society aggravating socio-economic inequity. – Reproduced
650			_aCOVID-19, National Pharmaceutical Pricing Authority, NPPA, Oximeter _930858
773			_aIIPA Digest
906			_aPHARMACEUTICAL PRICING
942			_cAR